NYSE:NHWK NightHawk Biosciences (NHWK) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.26▼$0.5052-Week Range N/AVolume173,100 shsAverage Volume97,242 shsMarket Capitalization$10.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesTrendsStock AnalysisEarningsHeadlinesTrends Get NightHawk Biosciences alerts: Email Address Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About NightHawk Biosciences Stock (NYSE:NHWK)NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.Read More Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report NHWK Stock News HeadlinesJuly 21, 2024 | seekingalpha.comSCPXD Scorpius Holdings, Inc.April 29, 2024 | seekingalpha.comScorpius Holdings GAAP EPS of -$1.74July 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.March 19, 2024 | globenewswire.comScorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major UniversityMarch 14, 2024 | globenewswire.comScorpius Holdings Accepted as a Member of the US Government's BioMaP-ConsortiumMarch 12, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Closing of Public OfferingMarch 8, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Pricing of Public OfferingMarch 7, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Proposed Public Offering of Common StockJuly 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.March 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023March 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023February 13, 2024 | uk.finance.yahoo.comScorpius Holdings, Inc. (SCPX)February 7, 2024 | msn.comNightHawk Biosciences Debuts SCPX Ticker on NYSE AmericanFebruary 7, 2024 | msn.comNightHawk Biosciences Unveils New Name and TickerJanuary 31, 2024 | msn.comNightHawk Biosciences Strikes Key Licensing and Financing DealsJanuary 30, 2024 | finance.yahoo.comNightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing NoteJanuary 25, 2024 | finance.yahoo.comNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramJanuary 17, 2024 | finanznachrichten.deNightHawk Biosciences: NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientSee More Headlines Receive NHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NHWK CUSIPN/A CIK1476963 Webwww.nighthawkbio.com Phone919-240-7133FaxN/AEmployees77Year Founded2008Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,440,000.00 Net Margins-2,333.27% Pretax Margin-2,546.97% Return on Equity-91.62% Return on Assets-56.48% Debt Debt-to-Equity Ratio0.27 Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$6.38 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.82 per share Price / BookN/AMiscellaneous Outstanding Shares26,080,000Free Float21,935,000Market Cap$10.78 million OptionableOptionable Beta0.19 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jeffrey Alan Wolf J.D. (Age 61)Founder, Chairman of the Board, CEO & President Comp: $842.6kMr. William L. Ostrander (Age 56)CFO & Secretary Comp: $476.24kDr. Justin Stebbing FRCPFRCPath, M.A., M.D., Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr.F.A.C.S., M.D., Chief Medical AdvisorMs. Ania SzymanskaHead of QualityKey CompetitorsCalciMedicaNASDAQ:CALCTempest TherapeuticsNASDAQ:TPSTProMIS NeurosciencesNASDAQ:PMNAadi BioscienceNASDAQ:AADIMIRA PharmaceuticalsNASDAQ:MIRAView All Competitors NHWK Stock Analysis - Frequently Asked Questions How were NightHawk Biosciences' earnings last quarter? NightHawk Biosciences, Inc. (NYSE:NHWK) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.01. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.57 million. NightHawk Biosciences had a negative trailing twelve-month return on equity of 91.62% and a negative net margin of 2,333.27%. When did NightHawk Biosciences' stock split? NightHawk Biosciences's stock reverse split on Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. This page (NYSE:NHWK) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NightHawk Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NightHawk Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
